NeoGenomics, Inc.: NeoGenomics Reports Third Quarter 2022 Results
Third Quarter Revenue Increased 6% to $129 MillionFORT MYERS, FL / ACCESSWIRE / November 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing